March 25, 2022 7:47am
The alternating positive and negative closes defines the infection of sentiment as it doesn’t take much to bounce or depress the cell and gene therapy sector
Pre-open indications: 5 SELL, 2 BUYs and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
TGIF
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.31% (+110 points), S&P futures are UP +0.39% (+17 points) and NASDAQ futures are UP +0.46% (+67 points)
U.S. stock futures were moving in Friday’s pre-market trading,
European markets were mixed as volatility continues,
Asia-Pacific markets were also mixed with Chinese stocks falling sharply
Henry’omics:
With one trading session left in the week, the S&P 500 and Nasdaq are up 1.3% and 2.1%, respectively. Both are on track for their second-straight winning week. The Dow is down 0.1% week to date. <CNBC>
Economic Data Docket: consumer sentiment reading from March as well as pending home sales data from February.
RegMed Investors’ (RMi) closing bell: “upside holding its own while riding the waves of a positive market” … https://www.regmedinvestors.com/articles/12359
Ebb and flow –
· March – 9 negative and 9 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (FIXX, CRBU and BLCM) added, 30 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
BUY:
Beam Therapeutics (BEAM +$1.90) after Wednesday’s -$4.90, Tuesday’s +$2.55 and Monday’s -$3.98) with a negative +$0.32 or +0.55% pre-open indication
Intellia Therapeutics (NTLA +1.77) with a positive +$1.69 or +2.35% pre-open indication
SELL:
Alnylam Pharmaceuticals (ALNY +$1.35) after Wednesday’s -$1.48, Tuesday’s +$1.40 and Monday’s -$2.82) with a negative -$0.59 or -0.36% pre-open indication.
Caribou Biosciences (CRBU -$0.09) with a positive -$0.20 or -2.10% pre-open indication
Sangamo Therapeutics (SGMO +$0.16) with a negative -$0.10 or -1.69% pre-open indication
uniQure NV (QURE +$0.59) with a negative -$0.35 or -2.025 pre-open indication
SELL into Strength:
Fate Therapeutics (FATE +$1.74) after Wednesday’s -$0.96 with a positive +$0.31 or +0.80% pre-open indication
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed flat again on Thursday with 34 shares traded after Wednesday with 4 shares traded, Tuesday’s down -$0.17 with 202 shares traded and Monday’s flat with 5 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
The BOTTOM LINE: The sector continued its bounce to a positive close Thursday from a negative Wednesday, a positive Tuesday, a negative Monday and last Friday’s positive close.
I would tread lightly on any buying opportunities, but many stocks are exposed to profit-taking or running to or from a bottom.
Sideways action or a modest pullback in the major indexes here wouldn't be a bad thing. It would let stocks finish off bases and form handles, or at least longer resistance areas. <IBD>
Hold-on (to the railing) as a portfolio weather these volatile sessions is an ordinary practice.
Again, I reiterate, “I’m never totally wrong but, not always wholly right after Monday, Tuesday, Wednesday, Thursday’s closes and last Friday’s week end.
There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another four (4) are due.
There is no clear trend ….
Earnings’ reporting on the horizon:
· Brainstorm Cell Therapeutics (BCLI), Monday, 3/28
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
